Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 12/20 | 0.62 |
| ▸ | MMP13 | P45452 | 8/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | MMP14 | P50281 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943747 | 1.00 | CXCR3 (0.62) | CXCR3MMP13MMP12MMP14KCNH2 | |
| SCHEMBL943411 | 0.83 | MMP13 (0.63) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942768 | 0.82 | MMP13 (0.62) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942644 | 0.82 | MMP13 (0.60) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942645 | 0.82 | MMP13 (0.60) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL941612 | 0.81 | CXCR3 (0.53) | CXCR3MMP13MMP12MMP14KCNH2 | |
| SCHEMBL940467 | 0.81 | MMP13 (0.56) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL4784651 | 0.80 | MMP13 (0.75) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL942141 | 0.80 | MMP13 (0.75) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL941431 | 0.80 | MMP13 (0.53) | MMP13MMP12MMP14KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | CXCR3 2067/4885MMP13 12/4885MMP12 2/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | CXCR3 2067/4885MMP13 12/4885MMP12 2/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | CXCR3 2867/4885MMP13 10/4885MMP12 5/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | CXCR3 1384/4885MMP13 19/4885MMP12 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.